Stockreport

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

Anavex Life Sciences Corp.  (AVXL) 
NASDAQ:AMEX Investor Relations: anavex.com/share-data
PDF ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcames [Read more]